<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754230</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-59164</org_study_id>
    <nct_id>NCT04754230</nct_id>
  </id_info>
  <brief_title>Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery</brief_title>
  <official_title>Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to assess the effectiveness of a dose of intravenous&#xD;
      tranexamic acid (TXA) given intraoperatively to reduce postoperative bleeding after&#xD;
      endoscopic sinus or nasal surgery (e.g. septoplasty, endoscopic sinus surgery, turbinate&#xD;
      surgery). This medication has been shown to decrease blood loss during this type of surgery,&#xD;
      but the implications for bleeding following surgery are unclear. Any impact on postoperative&#xD;
      bleeding will be assessed over the first 7 days following surgery leading up to the first&#xD;
      scheduled postoperative clinic visit. Patients will keep a standardized daily diary of their&#xD;
      bleeding experience by indicating on a 0-10 visual analog scale (VAS) their impression of&#xD;
      their bleeding.&#xD;
&#xD;
      The primary outcome is the patient-reported visual analog scale (VAS) bleeding score on each&#xD;
      day after surgery. The secondary outcomes include the the frequency with which the&#xD;
      otolaryngology resident service is requested to evaluate patients in the recovery unit for&#xD;
      postoperative bleeding concerns and the frequency of interventions such as application of&#xD;
      hemostatic materials, packing, cautery, and/or return to the operating room.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding VAS - POD1</measure>
    <time_frame>Postoperative Day 1</time_frame>
    <description>Patient-reported Visual Analog Scale - Bleeding Score Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding VAS - POD2</measure>
    <time_frame>Postoperative Day 2</time_frame>
    <description>Patient-reported Visual Analog Scale - Bleeding Score Day 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding VAS - POD3</measure>
    <time_frame>Postoperative Day 3</time_frame>
    <description>Patient-reported Visual Analog Scale - Bleeding Score Day 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding VAS - POD4</measure>
    <time_frame>Postoperative Day 4</time_frame>
    <description>Patient-reported Visual Analog Scale - Bleeding Score Day 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding VAS - POD5</measure>
    <time_frame>Postoperative Day 5</time_frame>
    <description>Patient-reported Visual Analog Scale - Bleeding Score Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding VAS - POD6</measure>
    <time_frame>Postoperative Day 6</time_frame>
    <description>Patient-reported Visual Analog Scale - Bleeding Score Day 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding VAS - POD7</measure>
    <time_frame>Postoperative Day 7</time_frame>
    <description>Patient-reported Visual Analog Scale - Bleeding Score Day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PACU Resident Evaluation Frequency</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Proportion of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Sinusitis</condition>
  <condition>Nasal Obstruction</condition>
  <condition>Turbinate; Hypertrophy Mucous Membrane</condition>
  <condition>Deviated Nasal Septum - Congenital</condition>
  <condition>Deviated Nasal Septum Acquired</condition>
  <arm_group>
    <arm_group_label>1,000mg IV Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will be given a 1,000mg dose of intravenous tranexamic acid via saline infusion 15 minutes prior to the completion of surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will not be given any extra intervention over their routine anesthetic care. They will continue to receive their normal saline infusion during surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)</intervention_name>
    <description>Medication administered 15 minutes prior to end of surgery.</description>
    <arm_group_label>1,000mg IV Tranexamic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled to undergo elective sinus or nasal surgery (e.g. septoplasty, inferior&#xD;
             turbinate reduction, endoscopic sinus surgery)&#xD;
&#xD;
          -  Age 18 or greater&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minors (age&lt;18)&#xD;
&#xD;
          -  Pregnant or may become pregnant by time of surgery&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Foreign citizens&#xD;
&#xD;
          -  Unable to provide consent&#xD;
&#xD;
          -  Known pro-thrombotic coagulation disorders&#xD;
&#xD;
          -  Active intranasal drug use (e.g. cocaine)&#xD;
&#xD;
          -  Surgery is for a sinonasal tumor or other sinus pathology not described in inclusion&#xD;
             criteria&#xD;
&#xD;
          -  Enrollment is in conflict with existing study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zara M. Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pundir V, Pundir J, Georgalas C, Fokkens WJ. Role of tranexamic acid in endoscopic sinus surgery - a systematic review and meta-analysis. Rhinology. 2013 Dec;51(4):291-7. doi: 10.4193/Rhino13.042. Review. Erratum in: Rhinology. 2014 Mar;52(1):77.</citation>
    <PMID>24260760</PMID>
  </reference>
  <reference>
    <citation>Ping WD, Zhao QM, Sun HF, Lu HS, Li F. Role of tranexamic acid in nasal surgery: A systemic review and meta-analysis of randomized control trial. Medicine (Baltimore). 2019 Apr;98(16):e15202. doi: 10.1097/MD.0000000000015202.</citation>
    <PMID>31008946</PMID>
  </reference>
  <reference>
    <citation>Alimian M, Mohseni M. The effect of intravenous tranexamic acid on blood loss and surgical field quality during endoscopic sinus surgery: a placebo-controlled clinical trial. J Clin Anesth. 2011 Dec;23(8):611-5. doi: 10.1016/j.jclinane.2011.03.004.</citation>
    <PMID>22137511</PMID>
  </reference>
  <reference>
    <citation>Kim DH, Kim S, Kang H, Jin HJ, Hwang SH. Efficacy of tranexamic acid on operative bleeding in endoscopic sinus surgery: A meta-analysis and systematic review. Laryngoscope. 2019 Apr;129(4):800-807. doi: 10.1002/lary.27766. Epub 2018 Dec 28.</citation>
    <PMID>30593688</PMID>
  </reference>
  <reference>
    <citation>El-Ozairy HSE, Mady OM, Tawfik GM, Elhennawy AM, Teaima AA, Ebied A, Huy NT. Outcomes of combined use of topical and intravenous tranexamic acid on surgical field quality during functional endoscopic sinus surgery: Randomized controlled trial. Head Neck. 2021 May;43(5):1389-1397. doi: 10.1002/hed.26610. Epub 2021 Jan 31.</citation>
    <PMID>33522019</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Zara M. Patel</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Obstruction</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plan to share data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

